Trial Profile
A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Raxibacumab (Primary)
- Indications Anthrax; Bacterial infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Human Genome Sciences
- 11 May 2021 Results of a pooled population pharmacokinetics analysis of data from 3 clinical trials (HGS1021-C1063,HGS1021-C1064 and HGS1021-C1069) published in the British Journal of Clinical Pharmacology
- 17 Dec 2012 Results from this trial supported US FDA approval of raxibacumab for inhalational anthrax
- 21 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.